Filing Details

Accession Number:
0000899243-22-002043
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-01-14 20:11:07
Reporting Period:
2021-07-28
Accepted Time:
2022-01-14 20:11:07
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1739410 Rallybio Corp RLYB () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1332141 Stephen Uden C/O Rallybio Corporation
234 Church Street, Suite 1020
New Haven CT 06510
See Remarks No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-07-28 709,127 $0.00 709,127 No 4 J Direct
Common Stock Acquisiton 2022-01-12 5,000 $10.55 714,127 No 4 P Direct
Common Stock Acquisiton 2022-01-13 4,193 $9.06 718,320 No 4 P Direct
Common Stock Acquisiton 2022-01-13 807 $9.62 719,127 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 J Direct
No 4 P Direct
No 4 P Direct
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Common Units Disposition 2021-07-28 4,820,000 $0.00 652,922 $0.00
Common Stock Series A-1 Preferred Units Disposition 2021-07-28 150,000 $0.00 23,557 $0.00
Common Stock Series A-2 Preferred Units Disposition 2021-07-28 100,000 $0.00 15,704 $0.00
Common Stock Series B Preferred Units Disposition 2021-07-28 107,891 $0.00 16,944 $0.00
Common Stock Option (Right to Buy) Acquisiton 2021-07-28 160,000 $0.00 160,000 $13.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 J Direct
0 No 4 J Direct
0 No 4 J Direct
0 No 4 J Direct
160,000 2031-07-28 No 4 A Direct
Footnotes
  1. The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the "Preferred Units") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation.
  2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.01 to $11.00, inclusive. The reporting person undertakes to provide to Rallybio Corporation, any security holder of Rallybio Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.
  3. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.29 to $9.28, inclusive.
  4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.29 to $10.28, inclusive.
  5. The option vests as to 25% of the underlying shares of Common Stock on July 28, 2022 and as to the remaining 75% of the underlying shares of Common Stock in 36 equal monthly installments thereafter.